Voluntary announcement licensing of dulaglutide injection in the U.S.
Filed with HKEX · · 2 pages · English
Summary by 6ix AI
The agreement includes upfront payments, milestone payments, and sales-based commissions for the company. The company plans to leverage its partner's strengths in R&D and sales to enhance market presence.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shandong Boan Biotechnology Company., Limited on 6ix
Later from Shandong Boan Biotechnology
- Poll results of the annual general meeting held on 22 June 2026
- Voluntary announcement cde approval of IND application for BA1203 (a masked anti-PD-1/IL-2 fusion protein)
- Next Day Disclosure Return
- Interim report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Shandong Boan Biotechnology into a list and get an email when it puts out news.
Follow Shandong Boan Biotechnology